Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Campigotto

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2014
Impact of informative censoring on the Kaplan-Meier estimate of progression-free survival in phase II clinical trialsFederico Campigotto, Edie Weller
Thrombosis Research|June 12, 2012
Accounting for death as a competing risk in cancer-associated thrombosis studiesFederico Campigotto, Donna Neuberg, Jeffrey I Zwicker
Blood|April 12, 2012
Abnormalities in IgA and IgM are associated with treatment-resistant ITPJon E Arnason, Federico Campigotto, Donna Neuberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2022
Reply to T. Olivier et alJedd D Wolchok, Harriet Kluger, Federico Campigotto, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|April 9, 2015
Recurrence of Venous Thromboembolism in Patients With Cancer Treated With WarfarinAriela L Marshall, Federico Campigotto, Donna Neuberg, et al.
Frontiers in Endocrinology|August 6, 2019
Safety and Efficacy of Subcutaneous Pasireotide in Patients With Cushing's Disease: Results From an Open-Label, Multicenter, Single-Arm, Multinational, Expanded-Access StudyMaria Fleseriu, Chioma Iweha, Luiz Salgado, et al.
Blood|January 10, 2015
Marked hyperferritinemia does not predict for HLH in the adult populationAlison M Schram, Federico Campigotto, Ann Mullally, et al.
British Journal of Haematology|January 10, 2012
Clinical significance of coagulation studies in predicting response to activated recombinant Factor VII in cardiac surgery patientsAlfred Ian Lee, Federico Campigotto, James D Rawn, et al.
Annals of the Rheumatic Diseases|March 20, 2021
JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinibPaqui G Traves, Bernard Murray, Federico Campigotto, et al.
Blood|June 6, 2015
Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyureaMaureen M Okam, Erica B Esrick, Elyse Mandell, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2014
Impact of informative censoring on the Kaplan-Meier estimate of progression-free survival in phase II clinical trialsFederico Campigotto, Edie Weller
Thrombosis Research|June 12, 2012
Accounting for death as a competing risk in cancer-associated thrombosis studiesFederico Campigotto, Donna Neuberg, Jeffrey I Zwicker
Blood|April 12, 2012
Abnormalities in IgA and IgM are associated with treatment-resistant ITPJon E Arnason, Federico Campigotto, Donna Neuberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2022
Reply to T. Olivier et alJedd D Wolchok, Harriet Kluger, Federico Campigotto, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|April 9, 2015
Recurrence of Venous Thromboembolism in Patients With Cancer Treated With WarfarinAriela L Marshall, Federico Campigotto, Donna Neuberg, et al.
Frontiers in Endocrinology|August 6, 2019
Safety and Efficacy of Subcutaneous Pasireotide in Patients With Cushing's Disease: Results From an Open-Label, Multicenter, Single-Arm, Multinational, Expanded-Access StudyMaria Fleseriu, Chioma Iweha, Luiz Salgado, et al.
Blood|January 10, 2015
Marked hyperferritinemia does not predict for HLH in the adult populationAlison M Schram, Federico Campigotto, Ann Mullally, et al.
British Journal of Haematology|January 10, 2012
Clinical significance of coagulation studies in predicting response to activated recombinant Factor VII in cardiac surgery patientsAlfred Ian Lee, Federico Campigotto, James D Rawn, et al.
Annals of the Rheumatic Diseases|March 20, 2021
JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinibPaqui G Traves, Bernard Murray, Federico Campigotto, et al.
Blood|June 6, 2015
Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyureaMaureen M Okam, Erica B Esrick, Elyse Mandell, et al.
Pageof 4